Parameter | CMFP (n=194) | Mitoxantrone (n=197) | Difference | 95% CI | P* |
---|---|---|---|---|---|
Mean progression-free months†| 7.975 | 6.666 | 1.309 | 0.047 to 2.648 | 0.05 |
Mean utility from randomisation to 1st disease progression | 0.904 | 0.895 | 0.009 | −0.006 to 0.022 | 0.16 |
Quality-adjusted progression-free survival | 7.208 | 5.965 | 1.243 | 0.119 to 2.487 | 0.04 |
Mean overall survival months‡ | 13.330 | 12.813 | 0.517 | −1.266 to 2.560 | 0.62 |
Mean utility from randomisation to death | 0.888 | 0.883 | 0.005 | −0.007 to 0.014 | 0.35 |
Quality-adjusted overall survival | 11.832 | 11.315 | 0.517 | −1.120 to 2.296 | 0.57 |